Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 440 of 641 · 7,691 filings

  • Lifetime Brands (LCUT) FY2024 10-K risk factors
    40 risks

    High dependence on major retailers Walmart and Costco creates significant customer concentration risk.

    Filed Mar 13, 2025
  • loanDepot (LDI) FY2024 10-K risk factors
    70 risks

    The company relies heavily on the mortgage market and interest rates for profitability. Project North Star aims to address market conditions and grow revenue. In-house servicing and reliance on warehouse credit lines present operational risks.

    Filed Mar 13, 2025
  • Lipocine (LPCN) FY2024 10-K risk factors
    58 risks

    Lipocine faces heavy regulatory, clinical, and commercial risks centered on its developmental neuroactive steroid and testosterone replacement portfolios. The company is heavily reliant on third-party single suppliers for active pharmaceutical ingredients and external partners for commercialization. Operations are entirely dependent on clinical trial success, FDA approvals, and adequate healthcare reimbursement.

    Filed Mar 13, 2025
  • Seres Therapeutics (MCRB) FY2024 10-K risk factors
    74 risks

    Seres Therapeutics faces severe going concern doubts, requiring near-term funding while advancing its clinical pipeline.

    Filed Mar 13, 2025
  • Medallion Financial (MFIN) FY2024 10-K risk factors
    41 risks

    Medallion Financial faces heavy risk concentration in consumer lending and non-prime recreation loans. The company relies heavily on brokered deposits for funding through Medallion Bank. Significant leverage includes $2.4 billion in outstanding indebtedness maturing near term.

    Filed Mar 13, 2025
  • MeiraGTx Holdings (MGTX) FY2024 10-K risk factors
    73 risks

    MeiraGTx faces ongoing operating losses, relies heavily on milestone payments from Johnson & Johnson, and requires additional capital to fund clinical development.

    Filed Mar 13, 2025
  • Milestone Pharmaceuticals (MIST) FY2024 10-K risk factors
    82 risks

    Milestone Pharmaceuticals faces ongoing operating losses and an accumulated deficit of $367.5 million as a clinical-stage biotech. The company is heavily dependent on the clinical development, regulatory approval, and commercialization of its lead product candidate, etripamil, for PSVT and AFib-RVR. Substantial additional capital will be required to fund operations, as existing cash is projected to last for at least the next 12 months.

    Filed Mar 13, 2025
  • Mach Natural Resources (MNR) FY2024 10-K risk factors
    87 risks

    Production and reserves are heavily concentrated in the Anadarko Basin with significant geographic and operational risks.

    Filed Mar 13, 2025
  • Mid Penn Bancorp (MPB) FY2024 10-K risk factors
    44 risks

    Mid Penn Bancorporation operates primarily in Pennsylvania with significant exposure to commercial real estate loans and interest rate fluctuations. The company is actively pursuing growth through acquisitions, notably the pending merger with William Penn Bancorporation.

    Filed Mar 13, 2025
  • MVB Financial (MVBF) FY2024 10-K risk factors
    42 risks

    MVB Financial relies heavily on West Virginia and Virginia real estate markets, representing 75.8% of total loans.

    Filed Mar 13, 2025
  • PCB Bancorp (PCB) FY2024 10-K risk factors
    41 risks

    PCB Bancorp faces high geographic and demographic concentration in California and Korean-American immigrant communities. Operations heavily depend on commercial and real estate lending, government-guaranteed loan programs, and interest rate spreads.

    Filed Mar 13, 2025
  • Ponce Financial Group (PDLB) FY2024 10-K risk factors
    51 risks

    Ponce Financial faces primary risks from credit exposure in its growing multifamily and construction loan portfolios within the New York market. The bank relies heavily on high-cost FHLBNY and FRBNY borrowings and is subject to stringent regulatory capital and CDFI status requirements. Operational risks, interest rate volatility, and local rent control laws significantly impact asset values and net interest margins.

    Filed Mar 13, 2025

Companies covered

4,011 companies

371 more under A